UY31800A - Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb - Google Patents
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbbInfo
- Publication number
- UY31800A UY31800A UY0001031800A UY31800A UY31800A UY 31800 A UY31800 A UY 31800A UY 0001031800 A UY0001031800 A UY 0001031800A UY 31800 A UY31800 A UY 31800A UY 31800 A UY31800 A UY 31800A
- Authority
- UY
- Uruguay
- Prior art keywords
- erbb
- inhibitor
- cmet
- treatment method
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
La presente invención se refiere a un método para tratar cánceres en un paciente, que comprende administrar al paciente cantidades terapéuticamente eficaces de : a) un compuesto de fórmula A: o una sal farmacéuticamente aceptable del mismo, donde R1 -R4, p, y q son como se han definido; y (b) un inhibidor de erbB que inhibe el receptor erbB-1 o erbB-2 o erbB-3 o una combinación de los mismos. El método de la presente invención satisface la necesidad de la técnica con el descubrimiento de una terapia combinada que muestra indicios de ser más eficaz que las terapias descritas previamente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5032208P | 2008-05-05 | 2008-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31800A true UY31800A (es) | 2009-11-10 |
Family
ID=41257222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001031800A UY31800A (es) | 2008-05-05 | 2009-04-30 | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
Country Status (19)
Country | Link |
---|---|
US (3) | US20090274693A1 (es) |
EP (1) | EP2274304A4 (es) |
JP (1) | JP2011519941A (es) |
KR (1) | KR20110004462A (es) |
CN (1) | CN102083824A (es) |
AR (1) | AR071631A1 (es) |
AU (1) | AU2009244453B2 (es) |
BR (1) | BRPI0912582A2 (es) |
CA (1) | CA2723699A1 (es) |
CL (1) | CL2009001063A1 (es) |
EA (1) | EA020779B1 (es) |
IL (1) | IL209057A0 (es) |
MX (1) | MX2010012101A (es) |
PE (1) | PE20091832A1 (es) |
SG (1) | SG190623A1 (es) |
TW (1) | TW201006829A (es) |
UY (1) | UY31800A (es) |
WO (1) | WO2009137429A1 (es) |
ZA (1) | ZA201007722B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007054550A1 (en) | 2005-11-11 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
TWI577664B (zh) | 2009-01-16 | 2017-04-11 | 艾克塞里克斯公司 | N-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途 |
EP2679600A1 (en) | 2009-03-25 | 2014-01-01 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
EP2451445B1 (en) | 2009-07-06 | 2019-04-03 | Boehringer Ingelheim International GmbH | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
TW201106972A (en) * | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
LT3351558T (lt) * | 2009-11-13 | 2020-06-10 | Daiichi Sankyo Europe Gmbh | Medžiaga ir būdai, skirti su her-3 susijusių ligų gydymui ir prevancijai |
US9724342B2 (en) | 2010-07-16 | 2017-08-08 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
BR112013004012B1 (pt) | 2010-08-20 | 2021-03-23 | Novartis Ag | Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
AU2011307304C1 (en) | 2010-09-27 | 2016-10-20 | Exelixis, Inc. | Dual inhibitors of MET and VEGF for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
AU2011348256A1 (en) * | 2010-12-23 | 2013-07-11 | Nestec S.A. | Drug selection for malignant cancer therapy using antibody-based arrays |
CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
CA2826751C (en) | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
WO2012151326A1 (en) * | 2011-05-02 | 2012-11-08 | Exelixis, Inc. | Method of treating cancer and bone cancer pain |
EA201490676A1 (ru) | 2011-09-22 | 2015-02-27 | Экселиксис, Инк. | Способ лечения остеопороза |
JP6208140B2 (ja) | 2011-10-20 | 2017-10-04 | エクセリクシス, インク. | キノリン誘導体の調製プロセス |
CN108047201A (zh) | 2011-11-14 | 2018-05-18 | 亚尼塔公司 | 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物 |
WO2013084147A2 (en) * | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
KR102078530B1 (ko) | 2012-01-31 | 2020-02-18 | 다이이찌 산쿄 가부시키가이샤 | 피리돈 유도체들 |
EP2844254A1 (en) | 2012-05-02 | 2015-03-11 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
CA2907334C (en) | 2013-03-15 | 2021-12-07 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
EP3057608A4 (en) | 2013-10-14 | 2017-10-11 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
US11045468B2 (en) * | 2014-02-04 | 2021-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient |
MX2016010266A (es) | 2014-02-14 | 2017-02-08 | Exelixis Inc | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. |
US10159666B2 (en) | 2014-03-17 | 2018-12-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
CA2944573C (en) * | 2014-04-03 | 2022-10-25 | Merck Patent Gmbh | Combinations of cancer therapeutics |
KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
UA121482C2 (uk) | 2014-08-05 | 2020-06-10 | Екселіксіс, Інк. | Комбінація інгібітору протеасом, яким є бортезоміб, та інгібітору c-met для лікування множинної мієломи |
JP6708130B2 (ja) | 2014-12-25 | 2020-06-10 | 小野薬品工業株式会社 | キノリン誘導体 |
FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
CN109069499A (zh) | 2016-04-15 | 2018-12-21 | 埃克塞里艾克西斯公司 | 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法 |
WO2017223180A2 (en) | 2016-06-21 | 2017-12-28 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
CN110437145A (zh) * | 2016-09-13 | 2019-11-12 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
AU2017378226A1 (en) | 2016-12-14 | 2019-06-20 | Janssen Biotech, Inc. | CD8A-binding fibronectin type III domains |
US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
ES2872923T3 (es) | 2017-01-26 | 2021-11-03 | Ono Pharmaceutical Co | Sal etanosulfonato de N-{5-[(6,7-dimetoxi-4-quinolinil)oxi]-2-piridinil}-2,5-dioxo-1-fenil-1,2,5,6,7,8-hexahidro-3-quinolinacarboxamida |
JP6771594B2 (ja) | 2017-02-15 | 2020-10-21 | 大鵬薬品工業株式会社 | 医薬組成物 |
JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
US11628222B2 (en) | 2019-10-14 | 2023-04-18 | Aro Biotherapeutics Company | CD71 binding fibronectin type III domains |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4458746B2 (ja) * | 2001-01-16 | 2010-04-28 | グラクソ グループ リミテッド | 癌の治療方法 |
EP2609919A3 (en) * | 2003-09-26 | 2014-02-26 | Exelixis, Inc. | c-Met modulators and methods of use |
ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
BRPI0619853A2 (pt) * | 2005-12-15 | 2016-08-23 | Astrazeneca Ab | combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero |
US20080058312A1 (en) * | 2006-01-11 | 2008-03-06 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
CN101605540A (zh) * | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
EP2076289B1 (en) * | 2007-04-13 | 2014-11-12 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
WO2008143666A2 (en) * | 2007-05-17 | 2008-11-27 | Genentech, Inc. | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
DK2194987T3 (en) * | 2007-09-10 | 2016-08-15 | Boston Biomedical Inc | Newly known group of stat3 signaling pathway inhibitors and cancer stem cell inhibitors |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en active Application Filing
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Application Discontinuation
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2274304A1 (en) | 2011-01-19 |
US20130142790A1 (en) | 2013-06-06 |
PE20091832A1 (es) | 2009-12-25 |
CN102083824A (zh) | 2011-06-01 |
CA2723699A1 (en) | 2009-11-12 |
MX2010012101A (es) | 2010-11-30 |
AU2009244453A1 (en) | 2009-11-12 |
EA201071268A1 (ru) | 2011-06-30 |
BRPI0912582A2 (pt) | 2015-07-28 |
KR20110004462A (ko) | 2011-01-13 |
JP2011519941A (ja) | 2011-07-14 |
AU2009244453B2 (en) | 2012-07-19 |
WO2009137429A1 (en) | 2009-11-12 |
EA020779B1 (ru) | 2015-01-30 |
ZA201007722B (en) | 2011-08-31 |
TW201006829A (en) | 2010-02-16 |
IL209057A0 (en) | 2011-01-31 |
EP2274304A4 (en) | 2012-05-30 |
AR071631A1 (es) | 2010-06-30 |
US20090274693A1 (en) | 2009-11-05 |
CL2009001063A1 (es) | 2010-09-24 |
SG190623A1 (en) | 2013-06-28 |
US20130150363A1 (en) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31800A (es) | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
CY1120866T1 (el) | Παρεμποδιστες dna-pk | |
CY1122624T1 (el) | Θεραπεια συνδυασμου του καρκινου | |
PA8740901A1 (es) | Compuestos organicos | |
CR20140410A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
HN2011000193A (es) | Derivados de piridazina como inhibidores de smo | |
DOP2012000243A (es) | Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales | |
CY1117200T1 (el) | Παραγωγα βενζυλαμινης ως αναστολεις καλλικρεϊνης πλασματος | |
EA201101507A1 (ru) | Способы лечения солидных опухолей | |
EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
NI201200181A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
DOP2014000058A (es) | 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante | |
EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
EA201290138A1 (ru) | Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция | |
ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
ECSP066457A (es) | 5-arilpirimidinas como agentes anti-cancer | |
CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
CY1121973T1 (el) | Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα | |
DOP2023000285A (es) | Restos de administración terapéutica novedosos y usos de estos | |
CY1122357T1 (el) | Αντικαρκινικος συνδυασμος που περιλαμβανει καμπαζιταξελη και σισπλατινη |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20190503 |